Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blinatumomab administration in one pediatric patient with B-precursor acute lymphoblastic leukemia
2016-002372-27Phase 4Completed
- Sponsor
- Borsod-Abaúj-Zemplén Megyei Központi Kórház és Egyetemi Oktatókórház
- Start
- May 2016
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of blinatumomab in acute lymphoblastic leukemia (ALL), sponsored by Borsod-Abaúj-Zemplén Megyei Központi Kórház és Egyetemi Oktatókórház. Started May 2016; status: completed.
02
Drugs
blinatumomab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on 2016-002372-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002372-27.